-
公开(公告)号：US20160136299A1
公开(公告)日：2016-05-19
申请号：US14878444
申请日：2015-10-08
Applicant: Genzyme Corporation
Inventor： Luis Z. Avila , Qun Zhou
CPC classification number: A61K47/6891 , A61K47/48646 , A61K47/549 , A61K47/6803 , A61K47/6817 , A61K47/6849 , A61K47/6889 , A61K2039/505 , C07K16/2809 , C07K16/2851 , C07K16/2893 , C07K16/32 , C07K16/40 , C07K2317/24 , C07K2317/40 , C07K2317/41 , C07K2317/522 , C07K2317/56 , C07K2317/71 , C07K2317/732 , C07K2317/76 , C07K2317/92 , C07K2317/94 , C07K2319/00
Abstract: The current disclosure provides binding polypeptides (e.g., antibodies), and targeting moiety conjugates thereof, comprising a site-specifically engineered glycan linkage within native or engineered glycans of the binding polypeptide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.
Abstract translation: 本公开提供了结合多肽（例如抗体）和靶向部分缀合物，其包含在结合多肽的天然或工程化聚糖中的位点特异性工程化的聚糖键。 本公开还提供了编码抗原结合多肽的核酸，用于制备这种抗原结合多肽的重组表达载体和宿主细胞。 还提供了使用本文公开的抗原结合多肽治疗疾病的方法。
-
公开(公告)号：US20160114052A1
公开(公告)日：2016-04-28
申请号：US14835236
申请日：2015-08-25
Applicant: ImmunoGen, Inc.
Inventor： Rajeeva Singh , Yelena Kovtun , Sharon D. Wilhelm , Ravi V.J. Chari
IPC: A61K47/48 , A61K31/5386
CPC classification number: A61K31/5386 , A61K47/54 , A61K47/60 , A61K47/6803 , A61K47/6843 , A61K47/6849 , A61K47/6851 , A61K47/6863 , A61K47/6889 , A61K47/6891 , C07D498/18 , C07K16/2803 , C07K16/30 , C07K2317/24 , Y02A50/491
Abstract: Linkers for binding drugs to cell binding agents are modified to hydrophilic linkers by incorporating a polyethylene glycol spacer. The potency or the efficacy of the cell-binding agent-drug conjugates is surprisingly enhanced several folds in a variety of cancer cell types, including those expressing a low number of antigens on the cell surface or cancer cells that are resistant to treatment. A method for preparing maytansinoids bearing a thioether moiety and a reactive group which allows the maytansinoid to be linked to a cell-binding agent in essentially a single step is also provided.
Abstract translation: 用于将药物与细胞结合剂结合的接头通过并入聚乙二醇间隔物而被修饰成亲水接头。 细胞结合剂 - 药物偶联物的效力或功效令人惊奇地增加了多种癌细胞类型的几倍，包括在细胞表面上表达低数目抗原的那些或对治疗有抗性的癌细胞。 还提供了一种制备具有硫醚部分的美登木素生物碱和允许美登木素生物碱在基本上单一步骤中与细胞结合剂连接的反应性基团的方法。
-
公开(公告)号：US09289511B2
公开(公告)日：2016-03-22
申请号：US14089343
申请日：2013-11-25
Applicant: The Boeing Company
Inventor： Maurice P. Bianchi
IPC: A61K47/48 , A61N5/06 , B82Y5/00 , A61K33/06 , A61K33/22 , A61K33/24 , A61K33/30 , A61K33/44 , A61K41/00 , C07K16/28 , A61B18/18 , A61N5/10
CPC classification number: A61K47/48376 , A61B18/18 , A61K33/06 , A61K33/22 , A61K33/24 , A61K33/30 , A61K33/44 , A61K41/0042 , A61K47/48092 , A61K47/48623 , A61K47/48723 , A61K47/549 , A61K47/6801 , A61K47/6865 , A61K47/6891 , A61N5/0624 , A61N5/10 , A61N2005/1085 , B82Y5/00 , C07K16/2833 , Y10S977/774 , Y10S977/904 , Y10S977/911
Abstract: The present disclosure relates to compositions and methods for the treatment of a disease, e.g., cancer or pathogenic infection, using a bioconjugated nanoparticle comprising a biocompatible quantum dot conjugated to a targeting moiety. The targeting moiety allows for the nanopaticle to bind to a cancer cell or pathogenic organism. The quantum dot, upon excitation by soft x-rays, emits electromagnetic radiation at a frequency of ultraviolet light, thereby allowing for the disruption of the DNA found in the cancer cell or pathogenic organism.
Abstract translation: 本公开涉及使用包含与靶向部分缀合的生物相容性量子点的生物共轭纳米颗粒来治疗疾病，例如癌症或致病性感染的组合物和方法。 靶向部分允许纳米颗粒结合癌细胞或致病生物体。 在通过软X射线激发时，量子点以紫外光的频率发射电磁辐射，从而允许破坏癌细胞或致病生物体中发现的DNA。
-
公开(公告)号：US20150355187A1
公开(公告)日：2015-12-10
申请号：US14654228
申请日：2013-12-19
Applicant: AKRIVIS TECHNOLOGIES, LLC
Inventor： Joel Berniac , Rajiv Panwar
CPC classification number: G01N33/581 , A61K47/60 , A61K47/645 , A61K47/6891 , C07K17/00 , C12N9/0065 , C12Q1/6841 , C12Y111/01007 , G01N33/58 , G01N33/582
Abstract: The invention provides methods for delivery of payloads to targets in samples using mixed payload polymers. The invention further provides reagents and kits for practicing the methods of the invention. The invention also provides methods for preparation of reagents for use in the methods of the invention.
Abstract translation: 本发明提供了使用混合有效载荷聚合物将有效载荷传递到样品中的目标的方法。 本发明还提供了用于实施本发明方法的试剂和试剂盒。 本发明还提供了用于制备用于本发明方法的试剂的方法。
-
公开(公告)号：US09173959B1
公开(公告)日：2015-11-03
申请号：US14807789
申请日：2015-07-23
Applicant: Stemcentrx, Inc.
Inventor： Robert A. Stull , Laura Saunders , Scott J. Dylla , Orit Foord , David Liu , Michael Torgov , Hui Shao
IPC: A61K39/395 , C07K16/18 , C12P21/08 , A61K47/48 , C07K16/28 , C07K16/30 , A61K31/5517 , G01N33/574 , A61K39/00
CPC classification number: A61K47/6803 , A61K31/551 , A61K31/5517 , A61K39/3955 , A61K45/06 , A61K47/48384 , A61K47/48407 , A61K47/48469 , A61K47/48538 , A61K47/48561 , A61K47/48592 , A61K47/48638 , A61K47/48715 , A61K47/48723 , A61K47/6809 , A61K47/6811 , A61K47/6813 , A61K47/6825 , A61K47/6829 , A61K47/6843 , A61K47/6849 , A61K47/6851 , A61K47/6855 , A61K47/6857 , A61K47/6859 , A61K47/6861 , A61K47/6867 , A61K47/6869 , A61K47/6889 , A61K47/6891 , A61K51/1096 , A61K2039/505 , A61K2039/572 , C07D487/04 , C07D487/16 , C07K16/18 , C07K16/28 , C07K16/2809 , C07K16/30 , C07K16/3023 , C07K16/3069 , C07K2317/20 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/34 , C07K2317/35 , C07K2317/53 , C07K2317/54 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/626 , C07K2317/70 , C07K2317/73 , C07K2317/732 , C07K2317/76 , C07K2317/77 , C07K2317/92 , C07K2319/30 , G01N33/57423 , G01N33/57492 , G01N2333/70596
Abstract: Pharmaceutical compositions to treat proliferative disorders are provided.
Abstract translation: 提供了治疗增殖性疾病的药物组合物。
-
Patent Agency Ranking
公开(公告)号：US09089617B2
公开(公告)日：2015-07-28
申请号：US14466951
申请日：2014-08-22
Applicant: STEM CENTRX, INC.
Inventor： Robert A. Stull , Laura Saunders , Scott J. Dylla , Orit Foord , David Liu , Michael Torgov , Hui Shao
IPC: A61K39/395 , C07K16/18 , C12P21/08 , A61K47/48 , C07K16/28 , C07K16/30 , A61K31/5517 , G01N33/574 , A61K39/00
CPC classification number: A61K47/6803 , A61K31/551 , A61K31/5517 , A61K39/3955 , A61K45/06 , A61K47/48384 , A61K47/48407 , A61K47/48469 , A61K47/48538 , A61K47/48561 , A61K47/48592 , A61K47/48638 , A61K47/48715 , A61K47/48723 , A61K47/6809 , A61K47/6811 , A61K47/6813 , A61K47/6825 , A61K47/6829 , A61K47/6843 , A61K47/6849 , A61K47/6851 , A61K47/6855 , A61K47/6857 , A61K47/6859 , A61K47/6861 , A61K47/6867 , A61K47/6869 , A61K47/6889 , A61K47/6891 , A61K51/1096 , A61K2039/505 , A61K2039/572 , C07D487/04 , C07D487/16 , C07K16/18 , C07K16/28 , C07K16/2809 , C07K16/30 , C07K16/3023 , C07K16/3069 , C07K2317/20 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/34 , C07K2317/35 , C07K2317/53 , C07K2317/54 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/626 , C07K2317/70 , C07K2317/73 , C07K2317/732 , C07K2317/76 , C07K2317/77 , C07K2317/92 , C07K2319/30 , G01N33/57423 , G01N33/57492 , G01N2333/70596
Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
Abstract translation: 提供了新型调节剂，包括抗体及其衍生物，以及使用这些调节剂治疗增殖性疾病的方法。
-
公开(公告)号：US09089615B2
公开(公告)日：2015-07-28
申请号：US14466842
申请日：2014-08-22
Applicant: STEM CENTRX, INC.
Inventor： Robert A. Stull , Laura Saunders , Scott J. Dylla , Orit Foord , David Liu , Michael Torgov , Hui Shao
IPC: A61K39/395 , C07K16/18 , C12P21/08 , A61K47/48 , C07K16/28 , C07K16/30 , A61K31/5517 , G01N33/574 , A61K39/00
CPC classification number: A61K47/6803 , A61K31/551 , A61K31/5517 , A61K39/3955 , A61K45/06 , A61K47/48384 , A61K47/48407 , A61K47/48469 , A61K47/48538 , A61K47/48561 , A61K47/48592 , A61K47/48638 , A61K47/48715 , A61K47/48723 , A61K47/6809 , A61K47/6811 , A61K47/6813 , A61K47/6825 , A61K47/6829 , A61K47/6843 , A61K47/6849 , A61K47/6851 , A61K47/6855 , A61K47/6857 , A61K47/6859 , A61K47/6861 , A61K47/6867 , A61K47/6869 , A61K47/6889 , A61K47/6891 , A61K51/1096 , A61K2039/505 , A61K2039/572 , C07D487/04 , C07D487/16 , C07K16/18 , C07K16/28 , C07K16/2809 , C07K16/30 , C07K16/3023 , C07K16/3069 , C07K2317/20 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/34 , C07K2317/35 , C07K2317/53 , C07K2317/54 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/626 , C07K2317/70 , C07K2317/73 , C07K2317/732 , C07K2317/76 , C07K2317/77 , C07K2317/92 , C07K2319/30 , G01N33/57423 , G01N33/57492 , G01N2333/70596
Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
Abstract translation: 提供了新型调节剂，包括抗体及其衍生物，以及使用这些调节剂治疗增殖性疾病的方法。
-
68.发明申请CHIMERIC SMALL MOLECULES FOR THE RECRUITMENT OF ANTIBODIES TO CANCER CELLS 有权用于诱导癌细胞的抗体的CHIMERIC小分子公开(公告)号：US20150018395A1
公开(公告)日：2015-01-15
申请号：US14480204
申请日：2014-09-08
Applicant: YALE UNIVERSITY
Inventor： David Spiegel , Ryan Murelli , Andrew Zhang
IPC: C07D249/04 , A61K45/06 , A61K31/4192
CPC classification number: C07K16/44 , A61K9/0019 , A61K31/4192 , A61K45/06 , A61K47/48023 , A61K47/48092 , A61K47/481 , A61K47/4833 , A61K47/48653 , A61K47/48723 , A61K47/54 , A61K47/549 , A61K47/55 , A61K47/646 , A61K47/68 , A61K47/6803 , A61K47/6869 , A61K47/6873 , A61K47/6891 , C07D249/04 , C07K16/3069 , C07K2317/31
Abstract: The present invention relates to chimeric chemical compounds which are used to recruit antibodies to cancer cells, in particular, prostate cancer cells or metastasized prostate cancer cells. The compounds according to the present invention comprise an antibody binding terminus (ABT) moiety covalently bonded to a cell binding terminus (CBT) through a linker and optionally, a connector molecule.
Abstract translation: 本发明涉及用于向癌细胞，特别是前列腺癌细胞或转移前列腺癌细胞募集抗体的嵌合化合物。 根据本发明的化合物包含通过接头和任选的连接体分子共价键合到细胞结合末端（CBT）的抗体结合末端（ABT）部分。
-
69.发明申请公开(公告)号：US20140086832A1
公开(公告)日：2014-03-27
申请号：US14074447
申请日：2013-11-07
Applicant: Immunomedics, Inc.
Inventor： William J. McBride , Christopher A. D'Souza , Chien-Hsing Chang , David M. Goldenberg
IPC: A61K39/395 , A61K31/4745 , A61K45/06
CPC classification number: A61K47/48723 , A61K31/655 , A61K39/3955 , A61K39/39583 , A61K47/595 , A61K47/6803 , A61K47/6851 , A61K47/6853 , A61K47/6885 , A61K47/6891 , A61K51/088 , A61K2039/505 , C07K1/1075 , C07K7/06 , C07K14/00 , C07K16/2803 , C07K16/2833 , C07K16/2863 , C07K16/2887 , C07K16/30 , C07K16/3007 , C07K16/3061 , C07K16/3076 , C07K16/3092 , C07K16/44 , C07K2317/24 , C07K2317/31 , C07K2317/35 , C07K2317/524 , C07K2317/526 , C07K2317/53 , C07K2317/55 , C07K2317/77 , C07K2319/33 , C07K2319/70 , Y02A50/403
Abstract: The present invention relates to methods and compositions for pretargeting delivery of therapeutic agents. In preferred embodiments, the pretargeting method comprises: a) administering a bispecific antibody with a first binding site for a disease-associated antigen and a hapten on a targetable construct; b) administering a targetable construct comprising at least one therapeutic agent. In preferred embodiments, the bispecific antibody is made by the dock-and-lock (DNL) technique. In a more preferred embodiment, the targetable construct comprises one or more SN-38 moieties.
Abstract translation: 本发明涉及用于预定靶递送治疗剂的方法和组合物。 在优选的实施方案中，预靶向方法包括：a）给予双特异性抗体与疾病相关抗原的第一结合位点和可靶向构建体上的半抗原; b）施用包含至少一种治疗剂的可靶向构建体。 在优选的实施方案中，双特异性抗体通过对接和锁定（DNL）技术制备。 在更优选的实施方案中，可靶向构建体包含一个或多个SN-38部分。
-
公开(公告)号：US20130095123A1
公开(公告)日：2013-04-18
申请号：US13656681
申请日：2012-10-20
Inventor： Hans-Georg Lerchen , Lars Linden , Sherif El Sheikh , Willuda Willuda , Charlotte Christine Kopitz , Joachim Schuhmacher , Simone Greven , Christoph Mahlert , Beatrix Stelte-Ludwig , Sven Golfier , Rudolf Beier , Iring Heisler , Axel Harrenga , Karl-Heinz Thierauch , Sandra Bruder , Heike Petrul , Hannah Jörißen , Sandra Borkowski
CPC classification number: A61K47/48715 , A61K31/40 , A61K31/4025 , A61K31/404 , A61K31/422 , A61K31/4245 , A61K31/5355 , A61K31/536 , A61K31/537 , A61K31/5377 , A61K39/3955 , A61K45/06 , A61K47/542 , A61K47/6803 , A61K47/6851 , A61K47/6859 , A61K47/6869 , A61K47/6889 , A61K47/6891 , C07K5/06 , C07K5/06052 , C07K7/02 , C07K7/06 , C07K16/18 , C07K16/2812 , C07K16/2863 , C07K16/30 , C07K2317/565 , C07K2317/76
Abstract: The present application relates to new binder-drug conjugates (ADCs) of N,N-dialkylauristatins that are directed against the target C4.4a, to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for treating and/or preventing illnesses, and also to the use of these ADCs for producing medicaments for treating and/or preventing illnesses, more particularly hyperproliferative and/or angiogenic diseases such as, for example, cancer diseases. Such treatments may be practised as a monotherapy or else in combination with other medicaments or further therapeutic measures.
Abstract translation: 本申请涉及针对目标C4.4a的N，N-二烷基硫酸钠的新粘合剂 - 药物共轭物（ADC），这些ADC的活性代谢物，制备这些ADC的方法，使用这些ADC 治疗和/或预防疾病，以及使用这些ADC用于制备用于治疗和/或预防疾病的药物，更具体地说是过度增殖和/或血管生成疾病，例如癌症疾病。 这样的治疗可以作为单一疗法来实施，或者与其它药物组合或进一步的治疗措施。
-
-
-
-
-
-
-
-
-
Search Results
221
records
(took 0.064 seconds)
